Pembrolizumab for the treatment of melanoma

References

• Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009;27:6199-206
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. Surveillance, epidemiology and end results. Available from: www.seer.cancer.gov/statfacts/
   Google Scholar
• Long GV, Stroyakovsky DL, Gogas H, et al. Combines BRAF and MEK Inhibition versus BRAF Inhibition alone in Melanoma. N Engl J Med 2014;371(20):1877-88
   PubMed Web of Science ®Google Scholar
• Schadendorf D, Hodi FS, Robert C, et al. Pooled analysis of long-term survival data from Phase II/III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 2015;33(17):1889-94
   PubMed Web of Science ®Google Scholar
• Ribas A. Tumor immunotherapy directed at PD-1. N Engl J Med 2012;366:2517-19
   PubMed Web of Science ®Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23
   PubMed Web of Science ®Google Scholar
• Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014;32:1020-30
   PubMed Web of Science ®Google Scholar
• Robert C, Long GV, Brady B, et al. Nivolumab in Previously Untreated Melanoma without BRAF Mutation. N Engl J Med 2015;372:320-30
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013;369:122-33
   PubMed Web of Science ®Google Scholar
• Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015;372(21):2006-17
   PubMed Web of Science ®Google Scholar
• Disis ML. Mechanism of action of immunotherapy. Semin Oncol 2014;41(Suppl 5):S3-13
   PubMed Web of Science ®Google Scholar
• Okazaki T, Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol 2007;19:813-24
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252-64
   PubMed Web of Science ®Google Scholar
• Ohaegbulam KC, Assal A, Lazar-Molnar E, et al. Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med 2015;21(1):24-33
   PubMed Web of Science ®Google Scholar
• Ott PA, Hodi FS. PD-1 and PD-L1 inhibition in the treatment of advanced melanoma. J OncoPathology 2013;1(4):83-9
   Google Scholar
• Tumeh PC, Harview CL, Yearly JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014;515(7528):568-71
   PubMed Web of Science ®Google Scholar
• Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti–PD-1) in melanoma. N Engl J Med 2013;369:134-44
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Tykodi SS, Chow LQM, et al. Safety and activity of Anti–PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366:2455-65
   PubMed Web of Science ®Google Scholar
• Blank C, Mackensen A. Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: and update on implications for chronic infections and tumor evasion. Cancer Immunol Immunother 2007;56:739-45
   PubMed Web of Science ®Google Scholar
• Cai G, Karni A, Oliveira EML, et al. PD-1 ligands, negative regulators for activation of naïve, memory, and recently activated human CD4+ T cells. Cell Immunol 2004;230(2):89-98
   PubMed Web of Science ®Google Scholar
• Iwai Y, Ishida M, Tanaka Y, et al. Involvement of PDL1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. PNAS 2002;99(19):12293-7
   PubMed Web of Science ®Google Scholar
• Korman A, Chen B, Wang C, et al. Activity of anti-PD-1 in murine tumor models: role of "host" PD-L1 and synergistic effect of anti-PD-1 and anti-CTLA-4 [Abstract]. J Immunol 2007;178:48-37
   Google Scholar
• Merck Sharp and Dohme Corp. FDA document for MK-3475- advisory committee meeting briefing materials. Available from: www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM373171.pdf [Last accessed 5 November 2013]
   Google Scholar
• Patnaik A, Kang SP, Tolcher AW, et al. Phase I study of MK-3475 (anti-PD-1) monoclonal antibody) in patients with advanced solid tumors. Presented at ASCO, Chicago, IL; June 2 2012
   Google Scholar
• Merck Sharp and Dohme Corp. Prescribing information for pembrolizumab (Keytruda) 2014. Available from: www.accessdata.fda.gov/drugsatfda_docs/label/2014/125514lbl.pdf
   Google Scholar
• Robert C, Ribas A, Wolchok JD, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 2014;384:1109-17
   PubMed Web of Science ®Google Scholar
• Ribas A, Puzanov I, Drummer R, et al. A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma. Presented at: Society for Melanoma Research, Zurich, Switzerland International Congress. 13–16 November, 2014
   Google Scholar
• Robert C, Schacter J, Long GV, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med 2015. [Epub ahead of print]
   Web of Science ®Google Scholar
• Wolchok JD, Hoos A, O’Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009;15:7412-20
   PubMed Web of Science ®Google Scholar
• Hodi FS, Ribas A, Daud A, et al. 2014 ASCO Annual Meeting: Evaluation of immune-related response criteria (irRC) in patients with advanced melanoma treated with the anti-PD-1 monoclonal antibody MK-3475. J Clin Oncol 2014;32(15 suppl):3006
   Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47
   PubMed Web of Science ®Google Scholar
• Lyle M, Lee J, Menzies AM. Lesion-specific patterns of response and progression with anti-PD-1 treatment in metastatic melanoma. Asia-Pacific J Clin Oncol 2014;10(Suppl 6):63
   Google Scholar
• Lipson EJ, Sharfman WH, Drake CG, et al. Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res 2013;19:462-8
   PubMed Web of Science ®Google Scholar
• Shahabi V, Postow MA, Tuck D, et al. Immune-priming of the tumor microenvironment by radiotherapy: rationale for combination with immunotherapy to improve anticancer efficacy. Am J Clin Oncol 2015;38(1):90-7
   PubMed Web of Science ®Google Scholar
• Hiniker SM, Knox SJ. Immunotherapy and Radiation. Seminars in Oncol 2014;41(6):702-13
   PubMed Web of Science ®Google Scholar
• Silk AW, Bassetti MF, West BT, et al. Ipilimumab and radiation therapy for melanoma brain metastases. Cancer Medicine 2013;2(6):899-906
   PubMed Web of Science ®Google Scholar
• Steiniche T, Danielsen AV, Wang Z, et al. 2014 ESMO Annual Meeting: PD-L1 expression and overall survival among patients with melanoma [abstract 1097P]. Ann Oncol 2014;25(Suppl 4):iv 380
   Google Scholar
• Daud A, Hamid O, Robert C, et al. Relationship between programmed death ligand 1 expression and clinical outcome in patients with melanoma treated with pembrolizumab [abstract 140]. Eur J Cancer 2014;50(Suppl 6):48
   Google Scholar
• Kefford R, Ribas A, Hamid O, et al. 2014 ASCO Annual Meeting: Clinical efficacy and correlation with tumour PD-L1 expression in patients with melanoma treated with the anti-PD-1 monoclonal antibody MK-3475. J Clin Oncol 2014;32(15 suppl):3005
   PubMedGoogle Scholar
• Madore J, Vilain RE, Menzies AM, et al. PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials. Pigment Cell Melanoma Res 2015;28(3):245-54
   PubMed Web of Science ®Google Scholar
• Kavakand H, Wilmott JS, Menzies AM, et al. PD-L1 expression and tumour infiltrating lymphocytes define different subsets of MAPK inhibitor treated melanoma patients. Clin Cancer Res 2014;27(6):1201
   Google Scholar
• De la Monte SM, Moore GW, Hutchins GM. Patterned distribution of metastases from malignant melanoma in humans. Cancer Res 1983;43(7):3427-33
   PubMed Web of Science ®Google Scholar
• Sampson JH, Carter JH, Friedman AH, et al. Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg 1998;88(1):11-20
   PubMed Web of Science ®Google Scholar
• Carlino MS, Atkins MB, Warneke CL, et al. Differences between Australia (OZ) and the United States (US) in the patterns, prognosis, and treatment of melanoma CNS metastases: analysis from the PHAMOUS (prognostic heterogeneity in patients with advanced melanoma between OZ and the US) study. Pigment Cell Melanoma Res 2010;23:874-1004
   Google Scholar
• Fife KM, Colman MH, Stevens GN, et al. Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol 2004;22(7):1293-300
   PubMed Web of Science ®Google Scholar
• Long GV, Trefzer U, Davies MA, et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 2012;13(11):1087-95
   PubMed Web of Science ®Google Scholar
• Margolin K, Ernstoff MS, Hamid O, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol 2012;13(5):459-65
   PubMed Web of Science ®Google Scholar
• Merelli B, Massi D, Cattaneo L, et al. Targeting the PD1/PD-L1 axis in melanoma: Biological rationale, clinical challenges and opportunities. Crit Rev Oncol Haematol 2014;89(1):140-65
   PubMed Web of Science ®Google Scholar
• Shin DS, Ribas A. The evolution of checkpoint blockade as a cancer therapy: what’s here, what’s next? Curr Opin Immunol 2015;33:23-35
   PubMed Web of Science ®Google Scholar
• Eggermont AMM, Chiarion-Sileni V, Grob J, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol 2015;16(5):522-30
   PubMed Web of Science ®Google Scholar
• Joseph RW, Elassais-Schaap J, Wolchok JD, et al. 2014 ASCO Annual Meeting: Baseline tumour size as an independent prognostic factor for overall survival in patients with metastatic melanoma treated with the anti-PD-1 monoclonal antibody MK-3475. J Clin Oncol 2014;32:15 Suppl
   Google Scholar
• Atkins MB, Kudchadkar RR, Sznol M, et al. Phase 2, multicenter, safety and efficacy study of pidilizumab in patients with metastatic melanoma. J Clin Oncol 2014(32 suppl): abstr 9001
   Google Scholar
• Hamid O, Sosman JA, Lawrence DP, et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma. J Clin Oncol 2013(31 suppl): abstr 9010
   PubMedGoogle Scholar
• Lutzky J, Antonia SJ, Blake-Haskins A, et al. A phase 1 study of MEDI4736, an anti-PD-L1 antibody, in patients with advanced solid tumours Proc Am Soc Clin Oncol 2014;32:3001
   Google Scholar
• Ribas A, Wolchok JD, Robert C, et al. Updated clinical efficacy of the anti-PD-1 monoclonal antibody pembrolizumab in 411 patients with melanoma. Pigment Cell Melanoma Res 2014;27(6):1222-3
   Google Scholar
• Robert C, Joshua AM, Weber JS, et al. Pembrolizumab for advanced melanoma: randomised comparison of two dosing schedules. 2014 ESMO Annual Meeting, 30 September 2014; Madrid, Spain, 2014
   Google Scholar